OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Squadron Capital Llc Sells 302,369 Shares of Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Squadron Capital Llc sold 302,369 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the sale, the insider owned 6,201,764 shares of the company’s stock, valued at approximately $130,299,061.64. This trade represents a 4.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Squadron Capital Llc also recently made the following trade(s):

• On Wednesday, September 2nd, Squadron Capital Llc sold 22,500 shares of OrthoPediatrics stock. The shares were sold at an average price of $23.35, for a total transaction of $525,375.00.
• On Friday, August 28th, Squadron Capital Llc sold 326,700 shares of OrthoPediatrics stock. The shares were sold at an average price of $23.04, for a total transaction of $7,527,168.00.
• On Tuesday, September 1st, Squadron Capital Llc sold 10,131 shares of OrthoPediatrics stock. The shares were sold at an average price of $23.10, for a total transaction of $234,026.10.
• On Wednesday, August 26th, Squadron Capital Llc sold 18,000 shares of OrthoPediatrics stock. The stock was sold at an average price of $24.28, for a total value of $437,040.00.
• On Tuesday, August 25th, Squadron Capital Llc sold 16,300 shares of OrthoPediatrics stock. The stock was sold at an average price of $24.74, for a total value of $403,262.00.
• On Monday, August 24th, Squadron Capital Llc sold 4,000 shares of OrthoPediatrics stock. The shares were sold at an average price of $25.75, for a total value of $103,000.00.

OrthoPediatrics Stock Up 2.3%

Shares of NASDAQ:KIDS opened at $22.06 on Friday. OrthoPediatrics Corp. has a 1 year low of $14.42 and a 1 year high of $26.74. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. The business’s 50-day moving average is $22.01 and its 200-day moving average is $19.04. The company has a market capitalization of $575.99 million, a price-to-earnings ratio of -13.13 and a beta of 0.99.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. The business had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Equities research analysts predict that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Analyst Ratings Changes

KIDS has been the subject of several research analyst reports. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Needham & Company LLC increased their target price on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Truist Financial set a $22.00 price target on shares of OrthoPediatrics in a report on Wednesday, August 5th. Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Finally, Piper Sandler reiterated an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, OrthoPediatrics currently has an average rating of “Moderate Buy” and an average target price of $26.44.

Key Stories Impacting OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics crossed the $70 million revenue level and reportedly increased its guidance, signaling continued demand for its pediatric orthopedic products and potentially stronger future growth. OrthoPediatrics Crosses $70M as Guidance Climbs Higher
• Positive Sentiment: Analyst sentiment remains favorable: nine analysts rate the stock Buy, one rates it Hold and one rates it Sell. The consensus rating is Moderate Buy with an average price target of $26.44; BTIG and Needham recently raised their targets to $29 and $35, respectively.
• Positive Sentiment: Institutional ownership is substantial at approximately 69%, while several investment firms—including Millennium Management, BlackRock, Granahan Investment Management and Wasatch Advisors—have recently increased or initiated positions.
• Neutral Sentiment: Reported short interest was zero shares as of September 10, leaving no meaningful short-covering catalyst or bearish short-position overhang.
• Negative Sentiment: Director David Pelizzon, also identified in related filings as major shareholder entities associated with Jennifer Pritzker and Squadron Capital, sold 302,369 shares at an average price of $21.01 for approximately $6.35 million. The sale reduced the reported holding by 4.65%, which may pressure sentiment, although the insider still retained about 6.2 million shares. SEC Insider Sale Filing

Hedge Funds Weigh In On OrthoPediatrics

A number of institutional investors have recently modified their holdings of KIDS. Millennium Management LLC lifted its holdings in shares of OrthoPediatrics by 48.0% in the 4th quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock worth $24,802,000 after purchasing an additional 452,840 shares in the last quarter. BlackRock Inc. purchased a new position in OrthoPediatrics during the 2nd quarter worth $24,347,000. Vanguard Group Inc. grew its position in OrthoPediatrics by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 961,330 shares of the company’s stock worth $17,813,000 after purchasing an additional 10,927 shares in the last quarter. Granahan Investment Management LLC grew its holdings in shares of OrthoPediatrics by 35.1% in the first quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock valued at $14,231,000 after acquiring an additional 232,760 shares in the last quarter. Finally, Wasatch Advisors LP grew its stake in OrthoPediatrics by 56.6% in the 2nd quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock valued at $9,865,000 after purchasing an additional 186,357 shares during the period. 69.05% of the stock is owned by institutional investors and hedge funds.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.